Formycon AG Reports Preliminary 2025 Fiscal Year Figures

Formycon AG has released its preliminary and unaudited figures for the 2025 fiscal year. Despite a robust increase in fourth-quarter revenues, the full-year projections fall short of the anticipated range of €55 million to €65 million, expected to be around €45 million. This shortfall results from extended negotiations for partner agreements and deferred milestone event recognition. Nevertheless, the Group's EBITDA is projected to reach the upper end of the forecast, at approximately €-12 million.

The company's adjusted EBITDA for the year is also set to outperform forecasts at around €-7 million, largely due to a positive at-equity result from its 50% stake in Bioeq AG. Working capital improvements are evident, expected to hit €73 million, buoyed by significant upfront payments and a placed corporate bond.